Study of sacituzumab tirumotecan for low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low-grade bladder cancer that hasn't spread into the bladder muscle (called non-muscle invasive bladder cancer, or NMIBC).
- Your doctor can see at least one tumor during a cystoscopy (a camera test) within the past 12 weeks.
- Your cancer is considered intermediate risk, such as having more than one tumor, a tumor larger than 3 cm, or having had a previous low-grade tumor come back within a year.
- You have a performance status of 0 to 2, meaning you can still do daily activities with little to some help.
- You do not have high-grade bladder cancer or cancer that has spread to the bladder muscle or beyond.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new medication, sacituzumab tirumotecan, for people with anal or rectal cancer that has spread or cannot be removed and has not responded to previous treatments. The drug is designed to target and kill cancer cells.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.